Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT E554_K558del||gastrointestinal stromal tumor||predicted - sensitive||KIT Inhibitor||Binimetinib + Imatinib||Case Reports/Case Series||Actionable||In a Phase II trial, Gleevec (imatinib) and Mektovi (binimetinib) combination treatment had manageable toxicity and resulted in a 99% pathological response and 29% RECIST response in a patient with a rectal gastrointestinal stromal tumor harboring KIT E554_K558del (PMID: 35041493; NCT01991379).||35041493|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|